Holger Lode
#96,759
Most Influential Person Now
German pediatrician
Holger Lode's AcademicInfluence.com Rankings
Holger Lodephilosophy Degrees
Philosophy
#11774
World Rank
#16266
Historical Rank
Logic
#8576
World Rank
#10749
Historical Rank
Download Badge
Philosophy
Why Is Holger Lode Influential?
(Suggest an Edit or Addition)According to Wikipedia, Holger Lode is a German specialist for pediatrics. He is Professor and Chair of the Department of General Pediatrics and Pediatric Hematology and Oncology at the University Medicine Greifswald. He is also the director of the Center of Pediatrics and Adolescent Medicine in Greifswald. Lode is well known for his clinical and scientific work on immunotherapy of neuroblastoma.
Holger Lode's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mutational dynamics between primary and relapse neuroblastomas (2015) (257)
- Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles (2012) (214)
- Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. (2018) (192)
- Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. (1997) (191)
- An autologous oral DNA vaccine protects against murine melanoma. (2000) (179)
- Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. (1998) (178)
- Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. (2004) (172)
- NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin (2012) (165)
- Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. (1999) (136)
- A Dual-Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-Mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice1 (2001) (120)
- IFN-γ-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy1 (2001) (118)
- Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. (1997) (105)
- Immunocytokines: a promising approach to cancer immunotherapy. (1998) (103)
- Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. (2005) (102)
- Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. (2008) (93)
- Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy (2004) (86)
- In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy (2001) (79)
- Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. (1998) (78)
- Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartments (2012) (70)
- 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors (2017) (69)
- Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. (2012) (68)
- Targeted cytokines for cancer immunotherapy (2000) (67)
- Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. (2001) (67)
- Survivin minigene DNA vaccination is effective against neuroblastoma (2009) (66)
- Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) (2020) (66)
- Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study (2014) (64)
- Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. (1997) (63)
- Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients (2013) (63)
- Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. (2007) (62)
- Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. (1995) (62)
- Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. (2000) (61)
- Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH (1998) (61)
- Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. (2001) (58)
- T cell memory against colon carcinoma is long-lived in the absence of antigen. (1999) (57)
- EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. (2019) (55)
- Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. (2006) (55)
- Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. (1999) (54)
- Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO (2017) (51)
- NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy (2003) (49)
- PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO (2017) (49)
- Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. (2013) (49)
- Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. (2003) (49)
- Induction of apoptosis by enediyne antibiotic calicheamicin ϑII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner (2003) (48)
- Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. (2018) (46)
- Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis. (2012) (46)
- Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. (2005) (45)
- Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2 (2016) (45)
- Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. (2000) (44)
- Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. (1998) (43)
- Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. (2000) (41)
- Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival (2016) (41)
- A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity (2008) (41)
- Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response (2013) (40)
- Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. (1998) (39)
- Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. (1998) (38)
- Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes (2006) (37)
- A new development of triterpene acid‐containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia (2012) (37)
- Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation. (2002) (34)
- Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. (2001) (33)
- Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. (2003) (33)
- Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma (2020) (33)
- Ascorbic-acid-mediated iron release from cellular ferritin and its relation to the formation of DNA strand breaks in neuroblastoma cells (2005) (33)
- Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma (2015) (33)
- A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. (2002) (33)
- Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells (2017) (32)
- Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. (2005) (30)
- Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma (2017) (29)
- Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. (1998) (28)
- Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. (2017) (26)
- Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. (1990) (25)
- Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma (2009) (25)
- ORIGINAL ARTICLE: Supporting the Hypothesis of Pregnancy As a Tumor: Survivin Is Upregulated in Normal Pregnant Mice and Participates in Human Trophoblast Proliferation (2007) (24)
- Multidrug resistance‐1 (MDR‐1): a new target for T cell‐based immunotherapy (2005) (24)
- Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody (2014) (24)
- Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia. (2007) (22)
- Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs. (2002) (22)
- Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy (1998) (20)
- Targeting of heme oxygenase‐1 as a novel immune regulator of neuroblastoma (2016) (20)
- Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. (2003) (20)
- Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity (2013) (19)
- Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial). (2016) (18)
- Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma. (2009) (17)
- The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study (2016) (17)
- GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma (2020) (16)
- Mucoepidermoid carcinoma of the lung in a 6-year-old boy. (2012) (16)
- DNA Vaccination: Using the Patient's Immune System to Overcome Cancer (2010) (16)
- The RIST design: A molecularly targeted multimodal approach for the treatment of patients with relapsed and refractory neuroblastoma. (2013) (15)
- DNA Minigene Vaccination for Adjuvant Neuroblastoma Therapy (2004) (15)
- Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial. (2019) (15)
- Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice (2015) (15)
- Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. (2014) (13)
- Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma. (2003) (13)
- Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma. (2015) (13)
- Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase. (2003) (13)
- Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients. (2015) (13)
- Ascorbic acid induces lipid peroxidation on neuroectodermal SK-N-LO cells with high endogenous ferritin content and loaded with MAb-ferritin immunoconjugates. (1994) (12)
- Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial (2018) (12)
- Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2 (2019) (11)
- Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. (2013) (11)
- Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD2 antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma (2018) (11)
- The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial. (2018) (10)
- Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma (2016) (9)
- Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls. (2018) (9)
- Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. (2019) (9)
- Eradication of CD19+ leukemia by targeted calicheamicin θ. (2009) (9)
- What to do with targeted IL-2. (2000) (9)
- Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment (2021) (9)
- Nutrient mixture including vitamin C, L‐lysine, L‐proline, and epigallocatechin is ineffective against tumor growth and metastasis in a syngeneic neuroblastoma model (2008) (8)
- Spontaneous vesicoureteral reflux resolution in children: A ten-year single-centre experience (2013) (8)
- Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients. (2014) (8)
- Amplification of T Cell-Mediated Immune Responses by Antibody-Cytokine Fusion Proteins (2000) (7)
- Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma. (2016) (7)
- Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO. (2016) (6)
- Ferritin enhances production of DNA strand breaks by 6-hydroxydopamine, ascorbic acid and H2O2 in CCC PM2 bacteriophage DNA (1992) (6)
- GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18 (2022) (6)
- Fibrin degradation product D-dimer in the diagnosis of pulmonary embolism (1991) (6)
- Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood (2014) (6)
- Pilot Study of Hydrolytically Activated Paclitaxel Prodrug Therapy in Patients with Progressive Malignancies (2002) (6)
- Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial. (2014) (6)
- In vitro response of THP-1 derived macrophages to antimicrobially effective PHMB-coated Ti6Al4V alloy implant material with and without contamination with S. epidermidis and P. aeruginosa (2022) (6)
- Determination of ascorbic acid by isotachophoresis with regard to its potential in neuroblastoma therapy. (1993) (5)
- Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy (2020) (5)
- Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice (2018) (5)
- GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma (2021) (5)
- Impact of magnetic resonance urography and ultrasonography on diagnosis and management of hydronephrosis and megaureter in paediatric patients. (2012) (5)
- GM‐CSF as successful salvage therapy of metamizole (dipyrone)‐induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent (2016) (5)
- MYCN-targeting vaccines and immunotherapeutics (2016) (4)
- Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome? (2017) (4)
- Abstract CT410: Immune activation, clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients (2014) (3)
- AACR Special Conference in cancer research: ubiquitination in normal and cancer cells (2003) (3)
- Neuroblastoma with intracerebral metastases and the need for neurosurgery: a single-center experience. (2019) (3)
- Radiolabeled metaiodobenzylguanidine (mibg) in diagnosis and therapy of neuroblastoma - results from basic research (review). (1995) (3)
- Abstract A013: Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma (2019) (3)
- [Incidence and duration of therapy of pathological hip findings in U2 and U3 examinations (SNiP study)]. (2014) (3)
- Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials (2022) (2)
- Abstract A032: Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients (2016) (2)
- Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO (2020) (2)
- THE RIST DESIGN: A PROMISING MOLECULARLY TARGETED MULTIMODAL APPROACH FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY NEUROBLASTOMA (2011) (2)
- Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma (2021) (2)
- The role of 13-hydroxylinoleic acid in the activation of macrophages by lipopolysaccharide. (1990) (2)
- Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study (2020) (2)
- Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma (2019) (2)
- Angiogenesis, views and news. The 93rd Annual Meeting of the American Association for Cancer Research (2002) (2)
- Erratum: An autologous oral DNA vaccine protects against murine melanoma (Proceedings of the National Academy of Sciences of the United States of America (May 9, 2000) 97 (10) (5492-5497)) (2000) (2)
- P01.33. A new development of Triterpene Acids-containing extracts from Viscum album L. displays synergistic induction of apoptosis in childhood leukemia (2012) (2)
- The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta (2022) (1)
- Effects of Viscum album L. extracts in neuroblastoma in vitro and in vivo (2011) (1)
- Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients (2013) (1)
- Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. (2023) (1)
- Triage through telemedicine in paediatric emergency care—Results of a concordance study (2022) (1)
- Abstract 4758: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine (2010) (1)
- GD2 Peptide Mimotope DNA Vaccines for Anti-Neuroblastoma Immunotherapy. (2004) (1)
- Approaches to Passive and Active Vaccination against Neuroblastoma (2015) (1)
- A novel legumain DNA vaccine effectively eradicates neuroblastoma and induces long-term survival in vivo (2008) (1)
- Iron Containing Nucleosides as New Cytostatic Substances for Cancer and Leukemia Therapy, Especially for Therapy of Relapsed ALL in Childhoodtransfusion of Red Blood Cells under Shock Conditions in the Rat Microvasculature. (2004) (1)
- Gastric teratoma in a 6-month-old boy. (2012) (1)
- A NEW DEVELOPMENT of Triterpene Acids-CONTAINING Extracts FROM Viscum Album L. Displays Synergistic INDUCTION of Apoptosis In Childhood LEUKEMIA (2011) (1)
- Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments (2022) (1)
- Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells (2022) (1)
- Phase I bridging study of ch14.18/CHO long-term infusion in recurrent or refractory neuroblastoma patients in Japan. (2016) (0)
- Evaluation of clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in high-risk neuroblastoma patients (2013) (0)
- Splenic rupture and fungal endocarditis in a pediatric patient with invasive fusariosis after allogeneic hematopoietic stem cell transplantation for aplastic anemia: A case report (2022) (0)
- NK cells engineered to express the chimeric receptor scFv(ch14.18)-zeta-specifically lyse GD2 expressing neuroectodermal tumors (2009) (0)
- GD2 peptide mimotope DNA vaccines for anti-neuroblastoma immunotherapy (2004) (0)
- Mimotopes of the disialoganglioside GD2 elicit anti-GD2 antibodies recognising GD2 on melanoma cells. (2006) (0)
- Development of dual function MYCN-DNA vaccines for anti-neuroblastoma immunotherapy (2013) (0)
- Classification : Neoplasia Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug resistant T-cell leukemia (2003) (0)
- Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model (2014) (0)
- Association of regulatory- and helper-T- cells with inferior survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. (2018) (0)
- Xenogeneic DNA vaccination with Tyrosine hydroxylase against neuroblastoma (2008) (0)
- Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients (2022) (0)
- Genomic Analysis of Bone Marrow-Derived Disseminated Neuroblastoma Cells (2016) (0)
- Targeted Delivery of Tumor Suppressor MicroRNA-34a to Neuroblastoma Tumors Using Disialoganglioside GD2 Conjugated to Mesoporous Silica Nanoparticles (0)
- Xenogeneic tyrosine hydroxylase DNA vaccination is effective against neuroblastoma (48.14) (2007) (0)
- First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma (2022) (0)
- Quantitative Diffusion-Weighted MRI of Neuroblastoma (2023) (0)
- Integrated genomic analysis identifies specific alterations and activation of YAP in relapsed neuroblastoma (2015) (0)
- Abstract 1800: 4-HPR (fenretinide) sensitizes human neuroblastoma cells for antibody-independent and ch14.18-mediated NK cell killing (2011) (0)
- Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up (2022) (0)
- Role of fractalkine (CX3CL1) rich neuroblastoma microenvironments for ganglioside GD2 directed immunotherapy (2007) (0)
- Addition of systemic IL2 increases effectiveness of hu14.18-IL2 immunocytokine therapy against NXS2 murine neuroblastoma (2004) (0)
- Effective Induction of Apoptosis by Mistletoe Plant Extracts in an Acute Lymphoblastic Leukemia Model. (2006) (0)
- Ralph A. Reisfeld, PhD: In Memoriam (1926–2020) (2021) (0)
- induces complete protection against metastatic neuroblastoma Immunotherapy with a posttranscriptionally modified DNA vaccine (2013) (0)
- Analysis of survivin mRNA and protein expression during murine pregnancy (2007) (0)
- Are micronutrients effective against cancer? (2008) (0)
- Development of an IL-21 enhanced MYCN-DNA vaccine for anti-neuroblastoma immunotherapy (2011) (0)
- Carcinoembryonic Antigen-Transgenic Mice Immunity Against Colon Cancer in Trimer Induces T Cell-Mediated Protective Carcinoembryonic Antigen and CD 40 Ligand A Dual-Function DNA Vaccine Encoding (2001) (0)
- MDR-1 Recognition by Cytotoxic T Cells. (2004) (0)
- Detection of minimal neuroblastoma cell contamination using tyrosine hydroxylase nested RT-PCR depends on basal tyrosine hydroxylase gene expression (2007) (0)
- Abstract 2407: Establishment of a clinically applicable human tyrosine hydroxylase DNA vaccine for anti-neuroblastoma immunotherapy (2010) (0)
- Generation and characterization of ganglidiximab for active immunotherapy of neuroblastoma (2013) (0)
- Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours (2018) (0)
- Procedures for treating tumors and metastases using a combination of therapies and immunotherapies Antiangiogenic. (2000) (0)
- Peptide mutation analysis results in potent GD2 mimotope peptides for DNA vaccination against neuroblastoma (2006) (0)
- Genotyping of KIR/KIRL mismatch, FCGR2A, -3A and -3B polymorphisms in patients subject to high-risk neuroblastoma immunotherapy using melting curve analysis (2013) (0)
- Bone Marrow by Targeted Interleukin-2 Therapy Mediated Eradication of Neuroblastoma Metastases to - Natural Killer Cell (2013) (0)
- Enhancement of Lymphokine-Activated Killer Cell Cytotoxicity by Mistletoe Plant Extracts. (2005) (0)
- Establishment of a clinically applicable human tyrosine hdroxylase DNA vaccine for anti-neuroblastoma immunotherapie (2009) (0)
- 984 Population-Based Study to Evaluate the Neonatal Morbidity and Mortality in Maternal Diabetes (2012) (0)
- Abstract A28: Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma. (2013) (0)
- Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms. (2017) (0)
- Effect of interleukin-2 on long term infusion treatment regimen of ch14.18/CHO antibody on activity in relapsed/refractory neuroblastoma patients. (2016) (0)
- Strategien zur Immuntherapie beim Neuroblastom (2003) (0)
- Mimotope optimization for GD2 directed anti-neuroblastoma immunotherapy (2007) (0)
- The development of a new murine MYCN-amplified neuroblastoma cell line (2008) (0)
- Abstract 5679: Using droplet digital PCR to analyzeMYCNcopy number in plasma from patients with high-risk neuroblastoma (2017) (0)
- Fenretinide (4-HPR) as immunostimulator of the antibody-dependent (ADCC) and antibody-independent NK cell mediated cytotoxicity (AICC) on neuroblastoma (2013) (0)
- Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up (2022) (0)
- Partial or multi drug resistant NB cell lines are highly sensitive towards chimeric receptor expressing NK-92-scFv(ch14.18)-zeta (2011) (0)
- Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma. (2017) (0)
- Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy. (2020) (0)
- Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model (2023) (0)
- Therapeutic efficacy of natural compounds from Viscum album L. in acute lymphoblastic leukaemia (2011) (0)
- Therapeutic Efficacy of Natural Compounds From Viscum Album l. In Acute Lymphoblastic Leukemia (2010) (0)
- Immunomodulation following treatment with ch14.18 and interleukin 2 in patients with refractory neuroblastoma (2011) (0)
- Long-term infusion of anti-GD2 antibody ch14.18/CHO is active and less toxic in high-risk neuroblastoma patients (2013) (0)
- Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma (2023) (0)
- Molecular characterization of a new anti-idiotype antibody for active immunotherapy in neuroblastoma (2011) (0)
- 4-HPR (fenretinide) sensitizes human neuroblastoma cells for ch14.18-mediated NK cell and complement killing (2011) (0)
- Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity (2012) (0)
- Iconographies supplémentaires de l'article : Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies (2012) (0)
- Call for a European Paediatric Association/Union of National European Paediatric Societies and Associations Survey on National Child Health Care Services for European Children with Malignancies (2017) (0)
- Abstract 1808: Neuroblastoma cell lines established from progressive disease that exhibit partial or multi drug resistance are highly sensitive to chimeric receptor scFv(ch14.18)-zeta mediated NK cell killing (2011) (0)
- Abstract 2858: Binding characteristics of the immunocytokine hu14.18-IL2 and induction of human effector functions as anticipated mode of action. (2013) (0)
- HGG-13. Combined CDK inhibition and arginine-deprivation as targeted therapy for arginine-auxotrophic glioblastoma multiforme cells (2022) (0)
- Long-Lived in the Absence of Antigen T Cell Memory Against Colon Carcinoma Is (1999) (0)
- Immunocytokines: Versatile Molecules for Biotherapy of Malignant Disease (2003) (0)
- Abstract 5601: NK cells engineered to express the chimeric receptor scFv(ch14.18)-zeta specifically lyse GD2 expressing neuroectodermal tumors (2010) (0)
- BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells (2022) (0)
- Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models (2023) (0)
- Targeted cytokine delivery with recombinant antibody fusion proteins for therapeutic intervention (1997) (0)
- Acute Lymphoblastic Leukemia in a Case of Ring Chromosome (2008) (0)
- Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment. (2015) (0)
This paper list is powered by the following services:
Other Resources About Holger Lode
What Schools Are Affiliated With Holger Lode?
Holger Lode is affiliated with the following schools:
